Monitor for Phase 2 trial initiations in ARDS and GVHD in 1H 2026, with early data expected by year-end. The non-dilutive funding and cash runway through 2026 reduce near-term financing risk, making clinical readouts the key value drivers.
Price Chart
Executive Summary
MiNK Therapeutics reported Q4 2025 financial results showing a narrower-than-expected net loss of $0.56 per share (beat vs $0.68 consensus), driven by non-dilutive funding and advancing clinical programs. Key catalysts include Phase 2 trials for ARDS/hypoxemic pneumonia (initiation in 1H 2026, data by year-end) and graft-versus-host disease (first dosing expected May 2026), supported by NIH and philanthropic grants. The company ended 2025 with $13.4M cash, extended to 2026 via $3M raised from its ATM program.
Key Financial Metrics
Key Facts
- Q4 2025 net loss of $2.6M ($0.56/share), beating consensus of $0.68/share.
- Phase 2 trial for ARDS/hypoxemic pneumonia to initiate in 1H 2026, with early data expected by year-end.
- GVHD program fully funded by NIH STTR grant and Mary Gooze award; first patient dosing expected May 2026.
- Ended 2025 with $13.4M cash; raised $3M since year-end via ATM, providing runway through 2026.
- Appointed Melissa Orilall as Principal Financial Officer and Col. (Ret.) John Holcomb to the Board.
Financial Impact
Net loss of $2.6M ($0.56/share) for Q4 2025, beating consensus by $0.12/share.
Risk Factors
- High cash burn typical of early-stage biotech; future dilution possible if additional funding is needed.
- Clinical trial delays or negative data could significantly impact stock price.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-133346 |
| Document: inkt-ex99_1.htm | 0001193125-26-133346 |
| Document: 0001193125-26-133346-index-headers.html | 0001193125-26-133346 |
| Document: 0001193125-26-133346-index.html | 0001193125-26-133346 |
| Document: 0001193125-26-133346.txt | 0001193125-26-133346 |
| 8-K Data (Synthetic) | 0001193125-26-133346 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 13, 2026 7w ago | Press Release | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 6, 2026 8w ago | Press Release | $11.00 $11.23 | ▲ +2.09% | ▲ +1.49% | $12.44 (+13.09%) |
May 28, 2026 18w ago | Press Release | $12.20 $11.64 | ▼ −4.59% | ▼ −1.45% | $12.44 (+1.97%) |
May 20, 2026 19w ago | Press Release | $10.72 $12.14 | ▲ +13.25% | ▲ +12.51% | $12.44 (+16.04%) |
May 15, 2026 20w ago | 8-K | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 15, 2026 20w ago | Press Release | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 14, 2026 20w ago | Press Release | $10.51 $12.02 | ▲ +14.37% | ▲ +15.23% | $12.44 (+18.36%) |
May 12, 2026 20w ago | Press Release | $11.41 $12.19 | ▲ +6.84% | ▲ +8.56% | $12.44 (+9.03%) |
May 8, 2026 20w ago | Press Release | $10.95 $11.82 | ▲ +7.95% | ▲ +8.25% | $12.44 (+13.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access